StockData
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30
$9.20+0.07 (+0.77%)

Close on Nov 17, 2026Market cap $821.53MP/E –Yield –

Syndax Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

Syndax Pharmaceuticals's cash was $427.10M at Sep 30, 2026. For fiscal 2025 it was $394.07M, down 31.2% from the year before. Over ten years it grew 16.4% a year on average. The highest annual figure on record is $572.88M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$394.07M-31.2%
FY2024Dec 31, 2024$572.88M+0.4%
FY2023Dec 31, 2023$570.70M+19.9%
FY2022Dec 31, 2022$475.80M+8.2%
FY2021Dec 31, 2021$439.94M+50.1%
FY2020Dec 31, 2020$293.07M+390.3%
FY2019Dec 31, 2019$59.78M-26.1%
FY2018Dec 31, 2018$80.91M-37.7%
FY2017Dec 31, 2017$129.97M+23.4%
FY2016Dec 31, 2016$105.33M+21.8%
FY2015Dec 31, 2015$86.49M+764.1%
FY2014Dec 31, 2014$10.01M-0.9%
FY2013Dec 31, 2013$10.10M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$427.10M-2.0%
Q2 FY2026Jun 30, 2026$547.86M+20.3%
Q1 FY2026Mar 31, 2026$352.06M-31.3%
Q4 FY2025Dec 31, 2025$394.07M-31.2%
Q3 FY2025Sep 30, 2025$435.98M+11.9%
Q2 FY2025Jun 30, 2025$455.23M+7.1%
Q1 FY2025Mar 31, 2025$512.20M+17.9%
Q4 FY2024Dec 31, 2024$572.88M+0.4%
Q3 FY2024Sep 30, 2024$389.61M+7.2%
Q2 FY2024Jun 30, 2024$425.10M+6.6%
Q1 FY2024Mar 31, 2024$434.58M+0.5%
Q4 FY2023Dec 31, 2023$570.70M+19.9%
Q3 FY2023Sep 30, 2023$363.56M+7.6%
Q2 FY2023Jun 30, 2023$398.80M+8.7%
Q1 FY2023Mar 31, 2023$432.39M+8.7%
Q4 FY2022Dec 31, 2022$475.80M+8.2%
Q3 FY2022Sep 30, 2022$337.84M+47.1%
Q2 FY2022Jun 30, 2022$366.79M+44.9%
Q1 FY2022Mar 31, 2022$397.93M+46.7%
Q4 FY2021Dec 31, 2021$439.94M+50.1%
Q3 FY2021Sep 30, 2021$229.71M+35.0%
Q2 FY2021Jun 30, 2021$253.13M+35.5%
Q1 FY2021Mar 31, 2021$271.34M+174.1%
Q4 FY2020Dec 31, 2020$293.07M+390.3%
Q3 FY2020Sep 30, 2020$170.16M+135.6%
Q2 FY2020Jun 30, 2020$186.75M+131.9%
Q1 FY2020Mar 31, 2020$99.01M+6.8%
Q4 FY2019Dec 31, 2019$59.78M-26.1%
Q3 FY2019Sep 30, 2019$72.24M-19.4%
Q2 FY2019Jun 30, 2019$80.52M-18.2%
Q1 FY2019Mar 31, 2019$92.74M-18.1%
Q4 FY2018Dec 31, 2018$80.91M-37.7%
Q3 FY2018Sep 30, 2018$89.60M-25.7%
Q2 FY2018Jun 30, 2018$98.39M-24.3%
Q1 FY2018Mar 31, 2018$113.20M+21.7%
Q4 FY2017Dec 31, 2017$129.97M+23.4%
Q3 FY2017Sep 30, 2017$120.59M–
Q2 FY2017Jun 30, 2017$129.96M–
Q1 FY2017Mar 31, 2017$93.00M–
Q4 FY2016Dec 31, 2016$105.33M–

More Syndax Pharmaceuticals figures

See a number that looks wrong?